Felicity Thomas

Cases of monkeypox are rising around the world, but it is unlikely the virus will become a pandemic problem.

In this episode of Drug Digest, Pharmaceutical Technology editors, Felicity Thomas and Feliza Mirasol, examine the topic of emerging therapies in more detail, covering subjects such as the challenges of scale, the potential benefits of drug delivery innovation, importance of early analytical studies, the evolution of the regulatory landscape, and differences between regional regulatory requirements.

Advances in therapeutic modalities and an increase in molecular complexity have led to the need for an evolution in drug delivery approaches over the years.

Partnering with an experienced service provider can help companies unlock the commercial potential of new therapeutic approaches.

A long-running criminal case involving the theft of confidential data from a pharma giant is still unravelling, as more convictions are made.

The challenges of conducting protein characterization can be overcome through the use of technologies that empower scientists in their analytical work.

An early formulation strategy for tablets that is simple and scalable is recommended to ensure fewer downstream problems.

The AMR Action Fund has made its first investments, marking an important step forward for the partnership to achieve its goal of bringing new treatments to the market for priority pathogens.

In this episode of the Drug Solutions podcast, Felicity Thomas, European Editor, talks to a panel of experts on drug dosage forms trends that have been impactful in recent years and those that may have an impact in the future.

Technological advances are helping shape the dosage forms of the future.

Developers need to consider key challenges when approaching accelerated formulation strategies to ensure success.

Scientists can work to overcome the challenges associated with protein characterization through empowering technologies.

Continuous improvements in technologies and services will help cold chain operators meet future industry demand.

As Russia’s invasion of Ukraine continues, industry leaders speak out in condemnation of the actions taking place and pledge to provide aid to those in need.

As Europe moves closer to implementation of ISO IDMP standards, the bio/pharma industry is accelerating efforts to manage its data and documents more effectively.

As company revenues are gaining a boost from COVID-19, the issue of pricing is being debated once more.

Toxicology studies are an important and required aspect of drug development that are performed to ensure that drugs are deemed safe prior to patient administration and use in clinical trials.

Experience is an invaluable asset for outsourcing partners, particularly as more challenging method development services are in demand.

A key benefit for companies when outsourcing formulation development is the broad experience they can gain from a dedicated service provider, particularly for niche markets.

Shifting demands from industry innovators is leading to an increased need for flexible and agile outsourcing partners offering broad and integrated models.

Particle analysis provides assurances of the quality and performance of the final dosage form in pharmaceutical development.

An obvious theme for 2021 has been COVID-19, but the next 12 months will see industry and its people experiencing further change.

Poor solubility remains a big issue for drug development and, as such, is driving innovation in approaches and use of novel technologies to help overcome the associated challenges.

Overall, 2021 proved to be another good year for drug approvals in Europe, albeit with a slight disappointment for Alzheimer’s patients, but what should industry be watching out for in 2022?

Increased patient-centricity and alternative dosage forms require careful consideration when selecting the best taste-masking approach.

Particle analysis is a critical component of pharmaceutical development, providing assurances of the quality and performance of the final dosage form.

Pharma and biotech are ruling the roost in terms of university innovation, but European spinouts are still experiencing barriers to long-term success.

Jordi Serrat, Product & Technology Director, Azbil Telstar talks about the role of disruptive and digital technologies in aseptic processing.

Global supply chain experts examine implications of the DSCSA as well as topical considerations around the EU's FMD in this serialization video series ft. manufacturing, packaging, software, and regulatory experts.

Rafael Beaus, Global Consultancy Manager, Azbil Telstar, discusses Annex 1 and trends in aseptic production.